Skip to main content
Top
Published in: Endocrine 3/2012

01-12-2012 | Original Article

Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes

Authors: Tae Nyun Kim, Man Sik Park, Seong Keon Lee, Sae Jeong Yang, Kwan Woo Lee, Moon Suk Nam, Yong Soo Park, Jeong Taek Woo, Young Seol Kim, Sei Hyun Baik

Published in: Endocrine | Issue 3/2012

Login to get access

Abstract

The purpose of this study is to examine the association of A1C with beta-cell dysfunction, insulin resistance, and cardiovascular risk factors in Koreans with the relatively high risk for the future development of diabetes. This cross-sectional study recruited subjects from the pre-diabetic cohort of the Korea National Diabetes Program. Among study subjects (n = 616) aged 21–77 years with a history of hyperglycemia (fasting plasma glucose (FPG) ≥5.5 mmol/mL), analyses were conducted on 504 participants (296 women, 208 men) except for subjects with FPG ≥ 7.0 mmol/L or 120-min post-challenge plasma glucose ≥11.1 mmol/L or A1C ≥ 6.5 %. For insulin sensitivity and β-cell function classified by the categories of A1C levels, ∆Ins30-0/∆Glu30-0 was lower in the highest quartile group than other groups. Although there was no significant difference in HOMA-IR according to the A1C categories, even lowest A1C group (≤5.3 %) already included many subjects with abnormal glucose tolerance. A1C showed a significant association with hsCRP, number of metabolic syndrome (MetS) components and ∆Ins30-0/∆Glu30-0 after adjusting for age, gender, BMI, and medications whereas HOMA-IR was insignificantly associated with A1C. Stepwise regression analysis for A1C showed that A1C is independently and negatively associated with ∆Ins30-0/∆Glu30-0, and positively associated with hsCRP. Our study showed that higher A1C was associated with impaired early-phase insulin secretion, MetS, and low grade inflammation in Koreans with the relatively high risk for the future development of diabetes.
Literature
1.
go back to reference J.C. Chan, V. Malik, W. Jia, T. Kadowaki, C.S. Yajnik, K.H. Yoon, F.B. Hu, Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301, 2129–2140 (2009)PubMedCrossRef J.C. Chan, V. Malik, W. Jia, T. Kadowaki, C.S. Yajnik, K.H. Yoon, F.B. Hu, Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301, 2129–2140 (2009)PubMedCrossRef
2.
go back to reference K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998)PubMedCrossRef K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998)PubMedCrossRef
3.
go back to reference R.G. Barr, D.M. Nathan, J.B. Meigs, D.E. Singer, Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann. Intern. Med. 137, 263–272 (2002)PubMed R.G. Barr, D.M. Nathan, J.B. Meigs, D.E. Singer, Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann. Intern. Med. 137, 263–272 (2002)PubMed
4.
go back to reference Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20, 1183–1197 (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20, 1183–1197 (1997)
5.
go back to reference International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327–1334 (2009) International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327–1334 (2009)
6.
go back to reference Y. Tahara, K. Shima, Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18, 440–447 (1995)PubMedCrossRef Y. Tahara, K. Shima, Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18, 440–447 (1995)PubMedCrossRef
7.
go back to reference K.H. Tseng, Standards of medical care in diabetes—2006: response to the American Diabetes Association. Diabetes Care 29, 2563–2564 (2006). author reply 2564–2565PubMedCrossRef K.H. Tseng, Standards of medical care in diabetes—2006: response to the American Diabetes Association. Diabetes Care 29, 2563–2564 (2006). author reply 2564–2565PubMedCrossRef
8.
go back to reference C. Meyer, W. Pimenta, H.J. Woerle, T. Van Haeften, E. Szoke, A. Mitrakou, J. Gerich, Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29, 1909–1914 (2006)PubMedCrossRef C. Meyer, W. Pimenta, H.J. Woerle, T. Van Haeften, E. Szoke, A. Mitrakou, J. Gerich, Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29, 1909–1914 (2006)PubMedCrossRef
9.
go back to reference K. Faerch, A. Vaag, J.J. Holst, T. Hansen, T. Jorgensen, K. Borch-Johnsen, Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 32, 439–444 (2009)PubMedCrossRef K. Faerch, A. Vaag, J.J. Holst, T. Hansen, T. Jorgensen, K. Borch-Johnsen, Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 32, 439–444 (2009)PubMedCrossRef
10.
go back to reference M.A. Abdul-Ghani, C.P. Jenkinson, D.K. Richardson, D. Tripathy, R.A. DeFronzo, Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55, 1430–1435 (2006)PubMedCrossRef M.A. Abdul-Ghani, C.P. Jenkinson, D.K. Richardson, D. Tripathy, R.A. DeFronzo, Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55, 1430–1435 (2006)PubMedCrossRef
11.
go back to reference Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 28, 1039–1057 (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 28, 1039–1057 (1979)
12.
go back to reference Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1, S5–20 (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1, S5–20 (2003)
13.
go back to reference W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972)PubMed W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972)PubMed
14.
go back to reference A. Caumo, G. Perseghin, A. Brunani, L. Luzi, New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method. Diabetes Care 29, 2733–2734 (2006)PubMedCrossRef A. Caumo, G. Perseghin, A. Brunani, L. Luzi, New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method. Diabetes Care 29, 2733–2734 (2006)PubMedCrossRef
15.
go back to reference T.M. Wallace, J.C. Levy, D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004)PubMedCrossRef T.M. Wallace, J.C. Levy, D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004)PubMedCrossRef
16.
go back to reference M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)PubMedCrossRef M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)PubMedCrossRef
17.
go back to reference C.C. Jensen, M. Cnop, R.L. Hull, W.Y. Fujimoto, S.E. Kahn, Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 51, 2170–2178 (2002)PubMedCrossRef C.C. Jensen, M. Cnop, R.L. Hull, W.Y. Fujimoto, S.E. Kahn, Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 51, 2170–2178 (2002)PubMedCrossRef
18.
go back to reference S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr, J.A. Spertus, F. Costa, Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol. Rev. 13, 322–327 (2005)PubMed S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr, J.A. Spertus, F. Costa, Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol. Rev. 13, 322–327 (2005)PubMed
19.
go back to reference U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44, 1249–1258 (1995) U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44, 1249–1258 (1995)
20.
go back to reference V.A. Fonseca, Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin. Cornerstone 9, 51–59 (2008). discussion 60-51PubMedCrossRef V.A. Fonseca, Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin. Cornerstone 9, 51–59 (2008). discussion 60-51PubMedCrossRef
21.
go back to reference D. Edelman, M.K. Olsen, T.K. Dudley, A.C. Harris, E.Z. Oddone, Utility of hemoglobin A1c in predicting diabetes risk. J. Gen. Intern. Med. 19, 1175–1180 (2004)PubMedCrossRef D. Edelman, M.K. Olsen, T.K. Dudley, A.C. Harris, E.Z. Oddone, Utility of hemoglobin A1c in predicting diabetes risk. J. Gen. Intern. Med. 19, 1175–1180 (2004)PubMedCrossRef
22.
go back to reference C. Droumaguet, B. Balkau, D. Simon, E. Caces, J. Tichet, M.A. Charles, E. Eschwege, Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 29, 1619–1625 (2006)PubMedCrossRef C. Droumaguet, B. Balkau, D. Simon, E. Caces, J. Tichet, M.A. Charles, E. Eschwege, Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 29, 1619–1625 (2006)PubMedCrossRef
23.
go back to reference A.D. Pradhan, N. Rifai, J.E. Buring, P.M. Ridker, Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am. J. Med. 120, 720–727 (2007)PubMedCrossRef A.D. Pradhan, N. Rifai, J.E. Buring, P.M. Ridker, Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am. J. Med. 120, 720–727 (2007)PubMedCrossRef
24.
go back to reference K.K. Sato, T. Hayashi, N. Harita, T. Yoneda, Y. Nakamura, G. Endo, H. Kambe, Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 32, 644–646 (2009)PubMedCrossRef K.K. Sato, T. Hayashi, N. Harita, T. Yoneda, Y. Nakamura, G. Endo, H. Kambe, Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 32, 644–646 (2009)PubMedCrossRef
25.
go back to reference T. Shimazaki, T. Kadowaki, Y. Ohyama, K. Ohe, K. Kubota, Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl. Res. 149, 196–204 (2007)PubMedCrossRef T. Shimazaki, T. Kadowaki, Y. Ohyama, K. Ohe, K. Kubota, Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl. Res. 149, 196–204 (2007)PubMedCrossRef
26.
go back to reference L.S. Geiss, L. Pan, B. Cadwell, E.W. Gregg, S.M. Benjamin, M.M. Engelgau, Changes in incidence of diabetes in US adults, 1997–2003. Am. J. Prev. Med. 30, 371–377 (2006)PubMedCrossRef L.S. Geiss, L. Pan, B. Cadwell, E.W. Gregg, S.M. Benjamin, M.M. Engelgau, Changes in incidence of diabetes in US adults, 1997–2003. Am. J. Prev. Med. 30, 371–377 (2006)PubMedCrossRef
27.
go back to reference S.E. Kahn, R.L. Prigeon, D.K. McCulloch, E.J. Boyko, R.N. Bergman, M.W. Schwartz, J.L. Neifing, W.K. Ward, J.C. Beard, J.P. Palmer et al., Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42, 1663–1672 (1993)PubMedCrossRef S.E. Kahn, R.L. Prigeon, D.K. McCulloch, E.J. Boyko, R.N. Bergman, M.W. Schwartz, J.L. Neifing, W.K. Ward, J.C. Beard, J.P. Palmer et al., Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42, 1663–1672 (1993)PubMedCrossRef
28.
go back to reference R.N. Bergman. Orchestration of homeostasis of glucose metabolism. Journ Annu Diabetol Hotel Dieu, 127–138 (2007) R.N. Bergman. Orchestration of homeostasis of glucose metabolism. Journ Annu Diabetol Hotel Dieu, 127–138 (2007)
29.
go back to reference K.M. Utzschneider, R.L. Prigeon, D.B. Carr, R.L. Hull, J. Tong, J.B. Shofer, B.M. Retzlaff, R.H. Knopp, S.E. Kahn, Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care 29, 356–362 (2006)PubMedCrossRef K.M. Utzschneider, R.L. Prigeon, D.B. Carr, R.L. Hull, J. Tong, J.B. Shofer, B.M. Retzlaff, R.H. Knopp, S.E. Kahn, Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care 29, 356–362 (2006)PubMedCrossRef
30.
go back to reference J. Hong, W.Q. Gu, Y.F. Zhang, Y.S. Yang, C.F. Shen, M. Xu, X.Y. Li, W.Q. Wang, G. Ning, The interplay of insulin resistance and beta-cell dysfunction involves the development of type 2 diabetes in Chinese obeses. Endocrine 31, 93–99 (2007)PubMedCrossRef J. Hong, W.Q. Gu, Y.F. Zhang, Y.S. Yang, C.F. Shen, M. Xu, X.Y. Li, W.Q. Wang, G. Ning, The interplay of insulin resistance and beta-cell dysfunction involves the development of type 2 diabetes in Chinese obeses. Endocrine 31, 93–99 (2007)PubMedCrossRef
31.
go back to reference C.A. Slentz, C.J. Tanner, L.A. Bateman, M.T. Durheim, K.M. Huffman, J.A. Houmard, W.E. Kraus, Effects of exercise training intensity on pancreatic beta-cell function. Diabetes Care 32, 1807–1811 (2009)PubMedCrossRef C.A. Slentz, C.J. Tanner, L.A. Bateman, M.T. Durheim, K.M. Huffman, J.A. Houmard, W.E. Kraus, Effects of exercise training intensity on pancreatic beta-cell function. Diabetes Care 32, 1807–1811 (2009)PubMedCrossRef
32.
go back to reference C.S. Shin, H.K. Lee, C.S. Koh, Y.I. Kim, Y.S. Shin, K.Y. Yoo, H.Y. Paik, Y.S. Park, B.G. Yang, Risk factors for the development of NIDDM in Yonchon County, Korea. Diabetes Care 20, 1842–1846 (1997)PubMedCrossRef C.S. Shin, H.K. Lee, C.S. Koh, Y.I. Kim, Y.S. Shin, K.Y. Yoo, H.Y. Paik, Y.S. Park, B.G. Yang, Risk factors for the development of NIDDM in Yonchon County, Korea. Diabetes Care 20, 1842–1846 (1997)PubMedCrossRef
33.
go back to reference A. Dehghan, I. Kardys, M.P. de Maat, A.G. Uitterlinden, E.J. Sijbrands, A.H. Bootsma, T. Stijnen, A. Hofman, M.T. Schram, J.C. Witteman, Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56, 872–878 (2007)PubMedCrossRef A. Dehghan, I. Kardys, M.P. de Maat, A.G. Uitterlinden, E.J. Sijbrands, A.H. Bootsma, T. Stijnen, A. Hofman, M.T. Schram, J.C. Witteman, Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56, 872–878 (2007)PubMedCrossRef
34.
go back to reference T.S. Han, N. Sattar, K. Williams, C. Gonzalez-Villalpando, M.E. Lean, S.M. Haffner, Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25, 2016–2021 (2002)PubMedCrossRef T.S. Han, N. Sattar, K. Williams, C. Gonzalez-Villalpando, M.E. Lean, S.M. Haffner, Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25, 2016–2021 (2002)PubMedCrossRef
35.
go back to reference F.B. Hu, J.B. Meigs, T.Y. Li, N. Rifai, J.E. Manson, Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53, 693–700 (2004)PubMedCrossRef F.B. Hu, J.B. Meigs, T.Y. Li, N. Rifai, J.E. Manson, Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53, 693–700 (2004)PubMedCrossRef
36.
go back to reference S. Nakanishi, K. Yamane, N. Kamei, M. Okubo, N. Kohno, Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 26, 2754–2757 (2003)PubMedCrossRef S. Nakanishi, K. Yamane, N. Kamei, M. Okubo, N. Kohno, Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 26, 2754–2757 (2003)PubMedCrossRef
37.
go back to reference A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, P.M. Ridker, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327–334 (2001)PubMedCrossRef A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, P.M. Ridker, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327–334 (2001)PubMedCrossRef
38.
39.
go back to reference S.M. Grundy, H.B. Brewer Jr, J.I. Cleeman, S.C. Smith Jr, C. Lenfant, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arter. Thromb. Vasc. Biol. 24, e13–e18 (2004)CrossRef S.M. Grundy, H.B. Brewer Jr, J.I. Cleeman, S.C. Smith Jr, C. Lenfant, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arter. Thromb. Vasc. Biol. 24, e13–e18 (2004)CrossRef
40.
go back to reference D.E. Laaksonen, H.M. Lakka, L.K. Niskanen, G.A. Kaplan, J.T. Salonen, T.A. Lakka, Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156, 1070–1077 (2002)PubMedCrossRef D.E. Laaksonen, H.M. Lakka, L.K. Niskanen, G.A. Kaplan, J.T. Salonen, T.A. Lakka, Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156, 1070–1077 (2002)PubMedCrossRef
41.
go back to reference R.L. Hanson, G. Imperatore, P.H. Bennett, W.C. Knowler, Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 51, 3120–3127 (2002)PubMedCrossRef R.L. Hanson, G. Imperatore, P.H. Bennett, W.C. Knowler, Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 51, 3120–3127 (2002)PubMedCrossRef
42.
go back to reference E.S. Ford, C. Li, N. Sattar, Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31, 1898–1904 (2008)PubMedCrossRef E.S. Ford, C. Li, N. Sattar, Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31, 1898–1904 (2008)PubMedCrossRef
43.
go back to reference E.S. Kang, Y.S. Yun, S.W. Park, H.J. Kim, C.W. Ahn, Y.D. Song, B.S. Cha, S.K. Lim, K.R. Kim, H.C. Lee, Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism 54, 206–211 (2005)PubMedCrossRef E.S. Kang, Y.S. Yun, S.W. Park, H.J. Kim, C.W. Ahn, Y.D. Song, B.S. Cha, S.K. Lim, K.R. Kim, H.C. Lee, Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. Metabolism 54, 206–211 (2005)PubMedCrossRef
44.
go back to reference J.M. Mooy, P.A. Grootenhuis, H. de Vries, P.J. Kostense, C. Popp-Snijders, L.M. Bouter, R.J. Heine, Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39, 298–305 (1996)PubMedCrossRef J.M. Mooy, P.A. Grootenhuis, H. de Vries, P.J. Kostense, C. Popp-Snijders, L.M. Bouter, R.J. Heine, Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39, 298–305 (1996)PubMedCrossRef
Metadata
Title
Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes
Authors
Tae Nyun Kim
Man Sik Park
Seong Keon Lee
Sae Jeong Yang
Kwan Woo Lee
Moon Suk Nam
Yong Soo Park
Jeong Taek Woo
Young Seol Kim
Sei Hyun Baik
Publication date
01-12-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9666-3

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue